Welcome to Third Coast Genomics

We are a multidisciplinary team focused on the implementation of clinical genomics.

About

Find Out More About Us

We genuinely want your project to succeed and to help improve lives through the power of clinical genomics.

We deliver expertise in medical practice, clinical informatics and information systems.

We are well versed in the latest clinical guidelines and understand how to make the case for coverage and reimbursement.

  • Clinical Expertise

    With decades of experience in rare genetic disease, we understand how these conditions typically espace detection and the difficulties of incorporating genetic testing into routine care.

  • Clinical and Research Bioinformatics

    We're intimately familiar with the intricacies of genetic test design. We have a track record of successful, CLIA validated test implementations using both custom and commercial software.

  • IT Systems Architecture

    We've built genomics solutions on-prem and in the cloud. We know how to handle the complexities of software testing and systems integration.

  • Patient Centered

    Our values are simple and direct. We start with patient needs and work backward. We believe that every sustainable clinical service delivers great benefits, minimizes harm, is cost-effective, and improves the health of the entire community.

Services

Check our Services

We operate throughout the entire span of an implementation. We take a staged approach so that you move forward when it makes sense.

Current State Analysis

Define target patient groups, outline current blockers, document existing infrastructure. Understand the impact of in-house genomic testing.

Test Planning

Implement testing best practices, scope personnel requirements, and select the best platforms and bioinformatics tools. Lay the groundwork for a successful implementation.

Systems Integrations

Connect standardized bioinformatics to your existing information systems. Customize LIMS with a focus on regulatory compliance and safety. Build custom reports and integrate with EHR.

F.A.Q

Frequently Asked Questions

Get answers to common questions concerning in-house genetic testing.

  • About 10% of your current patient population has a rare disease, and new sequencing technologies are opening the door to cost-effective testing. Your facility may already be using external reference labs for genetic tests. Bringing these tests in-house can have multiple benefits. Offering tests tailored to your needs will support long term sustainability and margin. Developing the local capability for testing will allow your doctors to more easily participate in the lab communication cycle, essential to resolve difficult cases. Rapid turnaround is becoming more common and local installations are an essential component.

  • There are now numerous studies in the peer reviewed literature which demonstrate that timely genetic testing solves the major diagnostic roadblock in rare disease. Benefits include improved decision making, change to more effective medicines, and avoidance of unnecessary and ineffective tests. There are also benefits to family members who can be evaluated using "cascade" testing. Your hospital may also benefit in that personnel and resources can be designed to meet your patient's needs.

  • Private health insurance, Medicaid, and Medicare all reimburse for guideline based clinical care including appropriate genetic testing. We can help you deploy testing policies that minimize pre-auth and testing obstacles.

  • Developing owned research databases attached to clinical information is proving to be an invaluable resource for new medical discoveries. NIH and foundation grants can be based on your unique resources. Many pharmaceutical companies are developing treatments for patients with rare diseases, and it is essential to identify the patients who might benefit from a clinical trial.

  • Lack of standards is often cited by payers as reasons to go slow on panel, exome, and genome reimbursement. By systematically collecting your lab and clinical experience, you will be enabled to share deidentified data with essential resources like ClinVar. Larger shared databases and more consistent curation will lead to more accurate diagnostic interpretations and faster turnaround times.